ArticleCanadian journal of gastroenterology & hepatology2021
Plasma Interleukin-6 Level: A Potential Prognostic Indicator of Emergent HBV-Associated ACLF.
Article in Canadian journal of gastroenterology & hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Extended analysis on peripheral blood cytokines correlated with hepatitis B virus viral load in chronically infected patients - a systematic review and meta-analysis.Frontiers in medicine · 2024Pooled it
- Feasibility and clinical outcomes of omental buttress-and-wrapping to reduce postoperative complications following minimally invasive spleen-preserving distal pancreatectomy: a retrospective cohort study.Surgical endoscopy · 2026Article
- Roles of AFP, AFP-L3, DCP and GP73 in Diagnosis of Hepatocellular Carcinoma and Prediction of Recurrence in Patients.Journal of Cancer · 2026Article
- Roles of inflammatory cytokines in the pathogenesis of hepatitis B virus-related acute-on-chronic liver failure and CAR-T therapy.Virology journal · 2025Article
- Golgi protein 73 and IL-6 as strong predictors of short-term prognosis in patients with HBV-ACLF.Scientific reports · 2025Article
- Thrombospondin 1 enhances systemic inflammation and disease severity in acute-on-chronic liver failure.BMC medicine · 2024Article
- A clinical study of non-bioartificial liver DPMAES support system in hepatitis B-related acute-on-chronic liver failure.Scientific reports · 2024Article
- Associations of Wnt5a expression with liver injury in chronic hepatitis B virus infection.BMC infectious diseases · 2023Article
- The Role of Interleukins in HBV Infection: A Narrative Review.Journal of personalized medicine · 2023Review
- The Role of Glutathione in Selected Viral Diseases.Antioxidants (Basel, Switzerland) · 2023Review
- Interleukin-8 predicts short-term mortality in acute-on-chronic liver failure patients with hepatitis B-related-related cirrhosis background.Annals of medicine · 2023Article
- IL-10 predicts the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure combined with spontaneous bacterial peritonitis.Frontiers in medicine · 2023Article
- Serum cytokine and chemokine profiles and disease prognosis in hepatitis B virus-related acute-on-chronic liver failure.Frontiers in immunology · 2023Article
- Lower level of IL-28A as a predictive index of the artificial liver support system in effective treatment of patients with HBV-ACLF.Journal of clinical laboratory analysis · 2022Article
- Roles of Interleukin-6-mediated immunometabolic reprogramming in COVID-19 and other viral infection-associated diseases.International immunopharmacology · 2022Review
- A practical nomogram based on serum interleukin-6 for the prognosis of liver failure.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify markers that predict the progression to hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). Methods: We recruited 125 patients with chronic hepatitis B (CHB) between September 2013 and March 2017. During hospitalization, 25 patients progressed to LF and were classified as the LF group, while the remaining 100 patients were classified as the non-LF (NLF) group. We compared the kinetic changes in clinical and immune indicators including age, total bilirubin level, prothrombin time, model for end-stage liver disease score, interleukin (IL)-6, IL-8, and IL-10 cytokine levels, and number of T helper 17 and regulatory T cells between groups to determine their association with progression to HBV-ACLF. The prognostic value of clinical and immune indicators was determined using the area under the receiver operating characteristic curve (AUC) value. Results: Cox regression analysis suggested that the plasma IL-6 level could predict CHB progression to HBV-ACLF (relative risk = 1.082, 95% confidence interval: 1.006-1.164; Conclusion: A high plasma IL-6 level in CHB patients could be an early biomarker for HBV-ACLF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.